Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 3/20 | 0.31 |
| ▸ | RARB | P10826 | 3/20 | 0.31 |
| ▸ | RARG | P13631 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ESRRG | P62508 | 2/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5678046 | 0.92 | TYR (0.36) | TP53HTTHCAR3RARARARB | |
| SCHEMBL5590181 | 0.83 | PRKCI (0.49) | PRKCIPTPN1PTPN11PTPN2PPARG | |
| SCHEMBL5680221 | 0.82 | PRKCI (0.44) | PRKCIPTPN1PTPN11PTPN2PPARG | |
| SCHEMBL5680235 | 0.79 | PRKCI (0.41) | PRKCIPTPN1PTPN11PTPN2PPARG | |
| SCHEMBL5196217 | 0.79 | PRKCI (0.47) | PRKCIPTPN1PTPN11PTPN2PPARG | |
| SCHEMBL5680839 | 0.78 | PRKCI (0.44) | PRKCIPPARGPPARAELANECTSG | |
| SCHEMBL5676020 | 0.78 | PRKCI (0.44) | PRKCIPPARGPPARAELANECTSG | |
| SCHEMBL5677938 | 0.77 | TYR (0.46) | PRKCITP53HTTPPARGPPARA | |
| SCHEMBL5680228 | 0.77 | TYR (0.46) | PRKCITP53HTTPPARGPPARA | |
| SCHEMBL5678255 | 0.76 | PRKCI (0.43) | PRKCITP53HTTHCAR3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | PRKCI 4096/4885TP53 1482/4885HTT 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.